Industry Briefs: Feb. 6, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Feb. 6, 2012
A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

FDA has approved Merck & Co.’s Janumet XR (sitagliptin and metformin HCl extended-release), a combination therapy for treating Type II diabetes. Read More

Florida Biologix has announced that it now meets European GMP requirements for aseptic fill–finish. Read More

NextPharma has opened a cold-chain and logistics warehouse in Werne, Germany. Read More

OctoPlus and Ferring Pharmaceuticals have entered into a formulation development and manufacturing contract. Read More

SCM Pharma has agreed to develop and manufacture an injectable neonatal product under development by BrePco BioPharma. Read More

Sobi and Biogen Idec have updated their agreement regarding development and commercialization of long-lasting recombinant Factor VIII and Factor IX hemophilia programs, which includes Biogen Idec assuming manufacturing rights. Read More

Xceleron is investing $2.4 million to locate all of the company’s business in its custom-built facility in Germantown, Maryland, which is expected to be fully operational by Mar. 31, 2012. Read More

People News

Auxilium Pharmaceuticals has named Andrew I. Koven as executive vice-president, chief administrative officer, and general counsel, and has appointed Mark A. Glickman as senior vice-president of sales. Read More

PCI Synthesis has made several executive appointments. Elie Saikali has been named director of manufacturing, and Mehdi Yazdi has been named director of quality control and analytical services. Don Dickinson has been named director of business development, and Paul Nichols has been appointed as director of cGMP for PCI’s early-phase clinical drug-substance development and manufacturing capabilities. Read More

Syntagon has appointed quality assurance expert George Köllner to provide GMP and stand-alone duties. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here